Form 4: VolitionRX Chief Medical Officer Receives Stock Award in Lieu of Cash Compensation

Andrew Retter, Chief Medical Officer of VolitionRX Ltd, was awarded 10,142 restricted stock units (RSUs) on March 1, 2025, in lieu of cash compensation.

Summary

• On March 1, 2025, Andrew Retter, the Chief Medical Officer of VolitionRX Ltd, received 10,142 restricted stock units (RSUs) under the company's 2024 Stock Incentive Plan.
• These RSUs were granted in place of cash compensation.
• The RSUs vest in three installments: 3,381 units on March 1, 2025, 3,381 units on April 1, 2025, and 3,380 units on May 1, 2025.
• The RSUs are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date.
• Upon vesting and settlement, Retter will receive common stock shares equal to the number of vested RSUs.
• Following the transaction, Retter beneficially owns 137,617 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and indicates confidence in the company's future, but it's not a major event.

Positives

• The award of RSUs aligns the Chief Medical Officer's interests with those of the shareholders.
• Using RSUs instead of cash compensation can help the company conserve cash.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Stock-based compensation is a common practice in the biotechnology industry to attract and retain talent, especially in companies that may be cash-strapped or prioritizing investment in research and development.

Comparison to Industry Standards

• Stock awards are a common component of executive compensation packages in the biotech industry.
• Companies like Exact Sciences and Guardant Health also utilize stock options and RSUs to incentivize their executives.
• The vesting schedule and the amount of RSUs granted are generally aligned with industry practices for companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns management's interests with theirs.
• Employees may see it as a positive sign of the company's commitment to its leadership.

Key Dates